Digital Content 
NEWS #PharmaBuzz
01 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/01/3091466/0/en/Novartis-Kisqali-reduces-risk-of-recurrence-in-younger-patients-with-early-breast-cancer-in-NATALEE-subgroup-analysis.html
28 Mar 2025
// PRESS RELEASE
https://www.suanfarma.com/apis-3/targeting-breast-cancer-with-precision-ribociclib-succinate-a-leading-cdk-4-6-inhibitor/
10 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/longer-term-novartis-kisqali-natalee-data-show-durable-reduction-in-distant-recurrence-in-broad-population-of-patients-with-early-breast-cancer-302327614.html
10 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/10/2994578/0/en/Longer-term-Novartis-Kisqali-NATALEE-data-show-durable-reduction-in-distant-recurrence-in-broad-population-of-patients-with-early-breast-cancer.html
10 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/10/2994354/0/en/Olema-Oncology-Presents-Updated-Clinical-Results-for-Palazestrant-in-Combination-with-Ribociclib-at-the-San-Antonio-Breast-Cancer-Symposium.html
27 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/27/2987957/0/en/Novartis-Kisqali-receives-European-Commission-approval-in-a-broad-population-of-patients-with-HR-HER2-early-breast-cancer-at-high-risk-of-recurrence.html
Share 